<?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName archivearticle.dtd?>
<?SourceDTD.Version 2.3?>
<?ConverterInfo.XSLTName nlm2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id>
    <journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id>
    <journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
    <journal-title-group>
      <journal-title>Frontiers in Pharmacology</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1663-9812</issn>
    <publisher>
      <publisher-name>Frontiers Media S.A.</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9538487</article-id>
    <article-id pub-id-type="publisher-id">1009996</article-id>
    <article-id pub-id-type="doi">10.3389/fphar.2022.1009996</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Pharmacology</subject>
        <subj-group>
          <subject>Methods</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>EFMSDTI: Drug-target interaction prediction based on an efficient fusion of multi-source data</article-title>
      <alt-title alt-title-type="left-running-head">Zhang et al.</alt-title>
      <alt-title alt-title-type="right-running-head">
        <ext-link xlink:href="https://doi.org/10.3389/fphar.2022.1009996" ext-link-type="uri">10.3389/fphar.2022.1009996</ext-link>
      </alt-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Zhang</surname>
          <given-names>Yuanyuan</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="aff2" ref-type="aff">
          <sup>2</sup>
        </xref>
        <xref rid="c001" ref-type="corresp">*</xref>
        <uri xlink:href="https://loop.frontiersin.org/people/816662/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wu</surname>
          <given-names>Mengjie</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/1939804/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Shudong</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">
          <sup>2</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/1075655/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Wei</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
      </contrib>
    </contrib-group>
    <aff id="aff1"><sup>1</sup><institution>School of Information and Control Engineering</institution>, <institution>Qingdao University of Technology</institution>, <addr-line>Qingdao</addr-line>, <addr-line>Shandong</addr-line>, <country>China</country></aff>
    <aff id="aff2"><sup>2</sup><institution>College of Computer science and Technology</institution>, <institution>China University of Petroleum (East China)</institution>, <addr-line>Qingdao</addr-line>, <addr-line>Shandong</addr-line>, <country>China</country></aff>
    <author-notes>
      <fn fn-type="edited-by">
        <p><bold>Edited by:</bold><ext-link xlink:href="https://loop.frontiersin.org/people/1072075/overview" ext-link-type="uri">Xun Wang</ext-link>, China University of Petroleum, Huadong, China</p>
      </fn>
      <fn fn-type="edited-by">
        <p><bold>Reviewed by:</bold><ext-link xlink:href="https://loop.frontiersin.org/people/1125397/overview" ext-link-type="uri">Yansen Su</ext-link>, Anhui University, China</p>
        <p><ext-link xlink:href="https://loop.frontiersin.org/people/875818/overview" ext-link-type="uri">Jin-Xing Liu</ext-link>, Qufu Normal University, China</p>
        <p><ext-link xlink:href="https://loop.frontiersin.org/people/1513767/overview" ext-link-type="uri">Xiao-Ying Yan</ext-link>, Xi’an Shiyou University, China</p>
      </fn>
      <corresp id="c001">*Correspondence: Yuanyuan Zhang, <email>yyzhang1217@163.com</email>
</corresp>
      <fn fn-type="other">
        <p>This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>23</day>
      <month>9</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <volume>13</volume>
    <elocation-id>1009996</elocation-id>
    <history>
      <date date-type="received">
        <day>02</day>
        <month>8</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>29</day>
        <month>8</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2022 Zhang, Wu, Wang and Chen.</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>Zhang, Wu, Wang and Chen</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
      </license>
    </permissions>
    <abstract>
      <p>Accurate identification of Drug Target Interactions (DTIs) is of great significance for understanding the mechanism of drug treatment and discovering new drugs for disease treatment. Currently, computational methods of DTIs prediction that combine drug and target multi-source data can effectively reduce the cost and time of drug development. However, in multi-source data processing, the contribution of different source data to DTIs is often not considered. Therefore, how to make full use of the contribution of different source data to predict DTIs for efficient fusion is the key to improving the prediction accuracy of DTIs. In this paper, considering the contribution of different source data to DTIs prediction, a DTIs prediction approach based on an effective fusion of drug and target multi-source data is proposed, named EFMSDTI. EFMSDTI first builds 15 similarity networks based on multi-source information networks classified as topological and semantic graphs of drugs and targets according to their biological characteristics. Then, the multi-networks are fused by selective and entropy weighting based on similarity network fusion (SNF) according to their contribution to DTIs prediction. The deep neural networks model learns the embedding of low-dimensional vectors of drugs and targets. Finally, the LightGBM algorithm based on Gradient Boosting Decision Tree (GBDT) is used to complete DTIs prediction. Experimental results show that EFMSDTI has better performance (AUROC and AUPR are 0.982) than several state-of-the-art algorithms. Also, it has a good effect on analyzing the top 1000 prediction results, while 990 of the first 1000DTIs were confirmed. Code and data are available at <ext-link xlink:href="https://github.com/meng-jie/EFMSDTI" ext-link-type="uri">https://github.com/meng-jie/EFMSDTI</ext-link>.</p>
    </abstract>
    <kwd-group>
      <kwd>drug-target prediction</kwd>
      <kwd>multi-source data</kwd>
      <kwd>topology and semantic graph</kwd>
      <kwd>similarity network fusion</kwd>
      <kwd>selective and weighted fusion</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source id="cn001">
          <institution-wrap>
            <institution>National Natural Science Foundation of China
</institution>
            <institution-id institution-id-type="doi">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id award-type="contract" rid="cn001">61902430 61873281 61972226</award-id>
      </award-group>
    </funding-group>
  </article-meta>
</front>
<body>
  <sec id="s1">
    <title>1 Introduction</title>
    <p>The accurate prediction of DTIs is worth that improves the speed and accuracy of new drug discovery. Although the traditional experimental methods have made some progress in DTIs identification, it is a costly, time-consuming process with a high failure rate (<xref rid="B35" ref-type="bibr">Whitebread et al., 2005</xref>; <xref rid="B3" ref-type="bibr">Avorn, 2015</xref>; <xref rid="B42" ref-type="bibr">Zhao et al., 2018</xref>; <xref rid="B18" ref-type="bibr">Liu et al., 2019</xref>). With the popularity of artificial intelligence concepts and technologies such as machine learning, more and more researchers are applying machine learning to predict DTIs, dramatically accelerating the new drug development process and revolutionizing the traditional drug development process. It provides accurate drug candidates for drug discovery, further reducing the cost and time of drug discovery. Currently, many researchers have focused on DTI prediction and achieved remarkable achievements through machine learning and deep learning (<xref rid="B17" ref-type="bibr">Li et al., 2016</xref>; <xref rid="B12" ref-type="bibr">Ezzat et al., 2019</xref>; <xref rid="B1" ref-type="bibr">Abbasi et al., 2020</xref>; <xref rid="B4" ref-type="bibr">Bagherian et al., 2021</xref>).</p>
    <p>Over recent years, a substantial number of computational methods have been developed for predicting drug discovery (<xref rid="B43" ref-type="bibr">Zhu et al., 2005</xref>; <xref rid="B26" ref-type="bibr">Sousa et al., 2006</xref>; <xref rid="B16" ref-type="bibr">Keiser et al., 2007</xref>; <xref rid="B5" ref-type="bibr">Bleakley and Yamanishi, 2009</xref>; <xref rid="B8" ref-type="bibr">Buza and Peška, 2017</xref>; <xref rid="B20" ref-type="bibr">Luo et al., 2017</xref>; <xref rid="B9" ref-type="bibr">Cheng et al., 2018</xref>; <xref rid="B21" ref-type="bibr">Olayan et al., 2018</xref>; <xref rid="B29" ref-type="bibr">Wan et al., 2018</xref>; <xref rid="B38" ref-type="bibr">Yan et al., 2019</xref>; <xref rid="B40" ref-type="bibr">Zeng et al., 2019</xref>; <xref rid="B34" ref-type="bibr">Wang et al., 2020a</xref>; <xref rid="B27" ref-type="bibr">Tang et al., 2020</xref>; <xref rid="B41" ref-type="bibr">Zeng et al., 2020</xref>; <xref rid="B2" ref-type="bibr">An and Yu, 2021</xref>; <xref rid="B11" ref-type="bibr">Chu et al., 2021</xref>; <xref rid="B37" ref-type="bibr">Yan et al., 2021</xref>; <xref rid="B44" ref-type="bibr">Zong et al., 2021</xref>). Target-based (<xref rid="B26" ref-type="bibr">Sousa et al., 2006</xref>), ligand similarity-based (<xref rid="B16" ref-type="bibr">Keiser et al., 2007</xref>) and machine learning-based (<xref rid="B43" ref-type="bibr">Zhu et al., 2005</xref>) methods are the three main-stream in prediction methods. However, obtaining the 3D structure of the protein is very time-consuming, making it difficult to use the target-based approach on a genome-wide scale. Similarly, the ligand-based target prediction usually depends on the structural characteristics of known target ligands. However, the number of known ligands from a single data source for the target protein is insufficient, and the prediction results of ligand-based methods may become unreliable. Currently, with the increasing availability of public data sets, the prediction of DTIs based on machine learning methods has been widely proposed and applied in recent years (<xref rid="B5" ref-type="bibr">Bleakley and Yamanishi, 2009</xref>). Moreover, huge amounts of multi-source data are being used to study the properties of drugs and targets to predict DTIs (<xref rid="B28" ref-type="bibr">Tao et al., 2022</xref>; <xref rid="B31" ref-type="bibr">Wang et al., 2022</xref>).</p>
    <p>In the calculation strategy of DTIs prediction, multiple drug and target data sources are often considered. Multi-source data of drugs and targets contain their inherent features and network topology information based on other attributes such as drug side effects. It is found that topology and semantic information often play different roles in the prediction task by analyzing the topological structure and feature graphs using the attention mechanism (<xref rid="B33" ref-type="bibr">Wang et al., 2020b</xref>). <xref rid="B27" ref-type="bibr">Tang et al. (2020)</xref> provided a marginalized denoising model to predict DTIs by calculating the similarities of target protein sequences and drug chemical structure. <xref rid="B11" ref-type="bibr">Chu et al. (2021)</xref> developed DTI-CDF model to predict DTIs through integrating target protein sequences and three drug side effects datasets. It uses multiple data sources to analyze drugs and targets. However, only the side effect and target protein sequences of drugs were considered, and other information about drugs and targets, such as the molecular structure of drugs and disease target correlation, was not considered, which may lose part of the information of drugs targets, resulting in inaccurate DTIs prediction. <xref rid="B21" ref-type="bibr">Olayan et al. (2018)</xref> proposed DDR model based on multi-source data of drug and target. It contains eight drug similarity networks and eight target similarity networks, which consider both topology and semantic in-formation. Although the fusion of multi-source data is considered, the contribution of different data sources is not considered. <xref rid="B41" ref-type="bibr">Zeng et al. (2020)</xref> proposed deepDTnet model based on multi-source data to predict DTIs. The feature vectors of drugs and tar-gets were learned and spliced for multi-source data of drugs and targets. They treated data from different sources equally, but different data often play different roles in DTIs prediction. An et al. proposed NEDTP model based on network embedding framework (<xref rid="B2" ref-type="bibr">An and Yu, 2021</xref>). They applied a random walk to extract the information of each node in the network and learn it as a low-dimensional vector. Finally, the GBDT model was constructed to complete the classification task. Although they consider how to extract and merge multi-source data, they learned the embedding features of drugs and targets by treating random walking paths through different networks equally, without fully considering the contributions of different data sources. Therefore, effectively fusing multi-source data is a challenge for accurately identifying DTIs through considering the topological and semantic information of multi-source data and exploring the weight of different networks. <xref rid="B38" ref-type="bibr">Yan et al. (2019)</xref> proposed MKLC-BiRW model to predict DTIs. Although they integrated multi-source heterogeneous data based on the kernel idea of KronrLS-MKL algorithm, they did not comprehensively organize the related data of drugs and targets.</p>
    <p>In this paper, we propose a framework named EFMSDTIs to predict DTIs based on the effective fusion of multi-source data. Specifically, EFMSDTI constructed similarity networks of multi-source drugs and targets from heterogeneous data, including the biological characteristics, molecular structure, biological function of drugs and targets. By classifying the different source data of drugs and targets, the drug and target similarity network is divided into the semantic graphs and topology graphs. We propose a selection and weighted entropy fusion algorithm based on SNF (<xref rid="B30" ref-type="bibr">Wang et al., 2014</xref>) for the semantic and topology graphs. Network embedding algorithm extracts low-dimensional features of drugs and targets. Finally, the features of drugs and targets learned were input into the prediction model to improve the prediction accuracy of DTIs. The results show that EFMSDTI has better performance over several state-of-art algorithms by classifying the data and treating the classified data with different weights during fusion.</p>
  </sec>
  <sec id="s2">
    <title>2 Materials and methods</title>
    <sec id="s2-1">
      <title>2.1 Overview of the EFMSDTI method</title>
      <p>Considering the contribution of different source data to DTIs prediction, a framework called EFMSDTI is proposed to predict DTIs. In <xref rid="F1" ref-type="fig">Figure 1</xref>, firstly, multi-source data of drugs and targets can be fused (including selective fusion and weighted fusion) or spliced by classifying multi-source data of them (see Results). For original data, it includes the topological graph (such as Drug-drug, Drug-disease, Drug-side Effect, Target-target, and Target-disease) and semantic graph (such as Drug similarities and Target similarities). According to the biological characteristics of the drug or target, drug or target related networks are divided into several categories, respectively. When there are multiple networks in a category, whether to fuse them into one network is determined according to the contribution of them to DTI prediction. Secondly, the networks are embedded to obtain the low-dimensional representations of drugs and targets based on the Deep neural Networks model for Graph Representations (DNGR) (<xref rid="B24" ref-type="bibr">Shaosheng et al., 2016</xref>), respectively. Finally, LightGBM (<xref rid="B23" ref-type="bibr">Qi, 2017</xref>) is used to predict the potential DTIs. EFMSDTI has the advantage that a selective weighted fusion algorithm based on similarity fusion is proposed according to the contribution of different source data to DTIs prediction. The aim is to explore an optimal scheme for predicting DTIs by classifying drugs and targets from multiple data sources according to their topology and semantic graphs.</p>
      <fig position="float" id="F1">
        <label>FIGURE 1</label>
        <caption>
          <p>EFMSDTI framework of predicting DTIs. EFMSDTI constructs 15 drug-related networks and target-related networks from heterogeneous multi-source data. Based on the contribution of the class network, the drug and target networks are fused or spliced after the network embedding. Through selective and weighted fusion based on SNF and extract low-dimensional vector of drugs and targets, then features are input into the LightGBM to predict DTIs. Among them, drug-related networks are DDI (Drug-drug), DD (Drug-disease), DSE (Drug-sideEffect), SD<sub>C</sub> (Chemical similarities), SD<sub>ATC</sub> (ATC similarities), SD<sub>P</sub> (Drug targets sequence similarities), SD<sub>MF</sub> (molecular function similarities), SD<sub>CC</sub> (cellular component similarities) and SD<sub>BP</sub> (biological process similarities), target-related networks are TTI (Target-target-interaction), TD (Target-disease), ST<sub>P</sub> (Target sequence similarities), ST<sub>MF</sub> (molecular function similarities), ST<sub>CC</sub> (cellular component similarities) and ST<sub>BP</sub> (biological process similarities).</p>
        </caption>
        <graphic xlink:href="fphar-13-1009996-g001" position="float"/>
      </fig>
    </sec>
    <sec id="s2-2">
      <title>2.2 Data source</title>
      <p>The drug and target are collected from the DrugBank database (v4.3) (<xref rid="B36" ref-type="bibr">Wishart et al., 2017</xref>), the Therapeutic Target Database (<xref rid="B39" ref-type="bibr">Yang et al., 2016</xref>), and the PharmGKB database (<xref rid="B15" ref-type="bibr">Hernandez-Boussard et al., 2008</xref>). Specifically, bioactivity data for drug–target pairs are collected from ChEMBL (v20) (<xref rid="B14" ref-type="bibr">Gaulton et al., 2012</xref>), BindingDB (<xref rid="B19" ref-type="bibr">Liu et al., 2007</xref>), and IUPHAR/BPS Guide to PHARMACOLOGY (<xref rid="B22" ref-type="bibr">Pawson et al., 2014</xref>). A total of 4978 DTIs are used to build a drug-target interaction network by 732 FDA-approved drugs and 1915 unique human targets (proteins), which include nine different data describing drugs and six data describing targets which refer to Zeng’s work (<xref rid="B41" ref-type="bibr">Zeng et al., 2020</xref>). The goal is to analyze the properties of drugs and targets from as many aspects and perspectives as possible in order to improve the prediction accuracy of DTIs.</p>
      <sec id="s2-2-1">
        <title>2.2.1 Drug-related networks</title>
        <p>For drugs, there are nine drug-related networks: (i) drug-drug interaction (DDI), (ii) drug-disease (DD), (iii) drug side-effect (DSE), (iv) chemical similarity (SD<sub>C</sub>), (v) Anatomical Therapeutic Chemical (ATC) (<xref rid="B10" ref-type="bibr">Cheng et al., 2013</xref>) similarity (SD<sub>ATC</sub>), (vi) protein sequence similarity (SD<sub>P</sub>), (vii) Go (SD<sub>GO</sub>) molecular function similarity (SD<sub>MF</sub>), (viii) Go cellular component similarity (ST<sub>CC</sub>), (ix) Go biological process similarity (ST<sub>BP</sub>). Where (ii) and (iii) calculate their similarity through the Jaccard coefficient.</p>
      </sec>
      <sec id="s2-2-2">
        <title>2.2.2 Target-related networks</title>
        <p>For targets, there are six target-related networks: (i) target-target interaction (TTI), (ii) target-disease (TD), (iii) target protein sequence similarity (ST<sub>P</sub>), (iv) Go (ST<sub>GO</sub>) molecular function similarity (ST<sub>MF</sub>), (v) Go cellular component similarity (ST<sub>CC</sub>), (vi) Go biological process similarity (ST<sub>BP</sub>). Where (ii) calculates its similarity through the Jaccard coefficient.</p>
      </sec>
      <sec id="s2-2-3">
        <title>2.2.3 Drug-target interaction network</title>
        <p>The drug-target interaction network is described by a bipartite graph <inline-formula id="inf1"><mml:math id="m1" overflow="scroll"><mml:mrow><mml:mi>G</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mi>D</mml:mi><mml:mo>,</mml:mo><mml:mi>T</mml:mi><mml:mo>,</mml:mo><mml:mi>R</mml:mi></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, where <inline-formula id="inf2"><mml:math id="m2" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mo>⋯</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf3"><mml:math id="m3" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mo>⋯</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula id="inf4"><mml:math id="m4" overflow="scroll"><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>|</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> describes the interaction between drug <inline-formula id="inf5"><mml:math id="m5" overflow="scroll"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and target <inline-formula id="inf6"><mml:math id="m6" overflow="scroll"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, and <inline-formula id="inf7"><mml:math id="m7" overflow="scroll"><mml:mrow><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>0,1</mml:mn></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, where <inline-formula id="inf8"><mml:math id="m8" overflow="scroll"><mml:mrow><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> indicate that drug <inline-formula id="inf9"><mml:math id="m9" overflow="scroll"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> interacts with target <inline-formula id="inf10"><mml:math id="m10" overflow="scroll"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>.</p>
      </sec>
    </sec>
    <sec id="s2-3">
      <title>2.3 Biometric classification of networks from multiple information</title>
      <p>In order to facilitate and effectively evaluate the contribution of different source data to DTI prediction, we divide them into topology and semantic graphs according to the information described by the network manually. Take drugs for example, the drug-drug similarity network, which is obtained through the association of various drugs, is considered as a topological graph; and drug-drug similarity networks based on drug attributes, such as drug molecular structure and drug classification, are considered as semantic graphs. Therefore, the association networks, including DDI, DSE, DD, TTI and TD, are the topology graphs of drugs and targets. The similarity networks between drugs (or targets) calculated based on multi-attribute information of drugs (or targets) are considered semantic graphs.</p>
      <sec id="s2-3-1">
        <title>2.3.1 Target classification</title>
        <p>The target-related networks contain two types of graphs: one is the topological graphs of the target, including the TTI and the TD, and the other is the semantic graphs of the target, including the ST<sub>P</sub> and the ST<sub>GO</sub>. The above topology and semantic graphs are further subdivided according to the described topology information and semantic similarity:<list list-type="simple"><list-item><p>• The first category <inline-formula id="inf11"><mml:math id="m11" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> is the TTI, there is a relationship of interaction between targets. If there is an interaction between <inline-formula id="inf12"><mml:math id="m12" overflow="scroll"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula id="inf13"><mml:math id="m13" overflow="scroll"><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, then <inline-formula id="inf14"><mml:math id="m14" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mi>T</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>, otherwise, <inline-formula id="inf15"><mml:math id="m15" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mi>T</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>;</p></list-item><list-item><p>• The second category <inline-formula id="inf16"><mml:math id="m16" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula> is the TD, it describes the relationship between the target and the disease. Where, <inline-formula id="inf17"><mml:math id="m17" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mi>D</mml:mi><mml:mo>∈</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mn>1</mml:mn></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf18"><mml:math id="m18" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> means that the target is associated with the disease;</p></list-item><list-item><p>• The third category <inline-formula id="inf19"><mml:math id="m19" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>3</mml:mn></mml:mrow></mml:math></inline-formula> is the similarity network ST<sub>P</sub>, it describes the similarity of protein sequences. The ST<sub>P</sub> is calculated by the Smith-Waterman algorithm (<xref rid="B25" ref-type="bibr">Smith and Waterman, 1981</xref>) based on target sequence;</p></list-item><list-item><p>• The fourth category <inline-formula id="inf20"><mml:math id="m20" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:math></inline-formula> is the similarity networks ST<sub>GO</sub>, it describes the function similarity of targets. It contains three networks: ST<sub>MF</sub>, ST<sub>CC</sub> and ST<sub>BP</sub> which are calculated by a graph-based semantic similarity measure algorithm (<xref rid="B32" ref-type="bibr">Wang et al., 2007</xref>). The target classification is shown in <xref rid="T1" ref-type="table">Table 1</xref>.</p></list-item></list>
</p>
        <table-wrap position="float" id="T1">
          <label>TABLE 1</label>
          <caption>
            <p>Classification of target-related data.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead valign="top">
              <tr>
                <th align="left" rowspan="1" colspan="1"/>
                <th align="left" rowspan="1" colspan="1">Target category</th>
                <th align="left" rowspan="1" colspan="1">Networks</th>
              </tr>
            </thead>
            <tbody valign="top">
              <tr>
                <td rowspan="2" align="left" colspan="1">Topological graphs</td>
                <td align="left" rowspan="1" colspan="1">
                  <inline-formula id="inf21">
                    <mml:math id="m21" overflow="scroll">
                      <mml:mrow>
                        <mml:mi>T</mml:mi>
                        <mml:mn>1</mml:mn>
                      </mml:mrow>
                    </mml:math>
                  </inline-formula>
                </td>
                <td align="left" rowspan="1" colspan="1">Target-target network TTI</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <inline-formula id="inf22">
                    <mml:math id="m22" overflow="scroll">
                      <mml:mrow>
                        <mml:mi>T</mml:mi>
                        <mml:mn>2</mml:mn>
                      </mml:mrow>
                    </mml:math>
                  </inline-formula>
                </td>
                <td align="left" rowspan="1" colspan="1">Target-disease network TD</td>
              </tr>
              <tr>
                <td rowspan="2" align="left" colspan="1">Semantic graphs</td>
                <td align="left" rowspan="1" colspan="1">
                  <inline-formula id="inf23">
                    <mml:math id="m23" overflow="scroll">
                      <mml:mrow>
                        <mml:mi>T</mml:mi>
                        <mml:mn>3</mml:mn>
                      </mml:mrow>
                    </mml:math>
                  </inline-formula>
                </td>
                <td align="left" rowspan="1" colspan="1">Similarity network of target protein sequence ST<sub>P</sub>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <inline-formula id="inf24">
                    <mml:math id="m24" overflow="scroll">
                      <mml:mrow>
                        <mml:mi>T</mml:mi>
                        <mml:mn>4</mml:mn>
                      </mml:mrow>
                    </mml:math>
                  </inline-formula>
                </td>
                <td align="left" rowspan="1" colspan="1">Three networks based on GO, ST<sub>MF</sub>, ST<sub>CC</sub> and ST<sub>BP</sub>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="s2-3-2">
        <title>2.3.2 Drug classification</title>
        <p>For drugs, the topological graphs include DDI, DD and DSE, the semantic graphs are SD<sub>C</sub>, SD<sub>ATC</sub>, SD<sub>P</sub> and SD<sub>GO</sub>. The network corresponding to the topology and semantic graphs of target are further subdivided into six categories:<list list-type="simple"><list-item><p>• The first category <inline-formula id="inf25"><mml:math id="m25" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> is the DDI. It is mainly determined by clinical data;</p></list-item><list-item><p>• The second category <inline-formula id="inf26"><mml:math id="m26" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula> are the DD and DSE. Drug similarity based on disease and side effects describes drug characteristics from the topological perspective of disease and side effects, respectively;</p></list-item><list-item><p>• The third category <inline-formula id="inf27"><mml:math id="m27" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>3</mml:mn></mml:mrow></mml:math></inline-formula> is the SD<sub>C</sub>. The <inline-formula id="inf28"><mml:math id="m28" overflow="scroll"><mml:mrow><mml:mi>S</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mi>c</mml:mi></mml:msub><mml:mo>∈</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>0,1</mml:mn></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> is calculated based on the molecular structure of drug pairs;</p></list-item><list-item><p>• The fourth category <inline-formula id="inf29"><mml:math id="m29" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:math></inline-formula> is the SD<sub>ATC</sub>. The <inline-formula id="inf30"><mml:math id="m30" overflow="scroll"><mml:mrow><mml:mi>S</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>T</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mn>1</mml:mn></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> is calculated based on Jaccard coefficient, and averaging ATC classification codes of each drug are up to five levels;</p></list-item><list-item><p>• The fifth category <inline-formula id="inf31"><mml:math id="m31" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:math></inline-formula> is the SD<sub>P</sub>, it describes the sequence similarity of targets associated with different drugs. The protein sequence similarity between drug pairs (SD<sub>P</sub>) is the average of the similarity of all drug targets;</p></list-item><list-item><p>• The sixth category <inline-formula id="inf32"><mml:math id="m32" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>6</mml:mn></mml:mrow></mml:math></inline-formula> is the SD<sub>GO</sub>. It describes the function similarity of targets associated with different drugs, including the similarity networks SD<sub>MF</sub>, SD<sub>CC</sub> and SD<sub>BP</sub>. Similar to the SD<sub>P</sub>, the GO similarity SD<sub>GO</sub> of drug <inline-formula id="inf33"><mml:math id="m33" overflow="scroll"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and drug <inline-formula id="inf34"><mml:math id="m34" overflow="scroll"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> is calculated by averaging the GO similarity of all drug targets. The drug classification is shown in <xref rid="T2" ref-type="table">Table 2</xref>.</p></list-item></list>
</p>
        <table-wrap position="float" id="T2">
          <label>TABLE 2</label>
          <caption>
            <p>Classification of drug-related data.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead valign="top">
              <tr>
                <th align="left" rowspan="1" colspan="1"/>
                <th align="left" rowspan="1" colspan="1">Drug category</th>
                <th align="left" rowspan="1" colspan="1">Networks</th>
              </tr>
            </thead>
            <tbody valign="top">
              <tr>
                <td rowspan="2" align="left" colspan="1">Topological graphs</td>
                <td align="left" rowspan="1" colspan="1">
                  <inline-formula id="inf35">
                    <mml:math id="m35" overflow="scroll">
                      <mml:mrow>
                        <mml:mi>D</mml:mi>
                        <mml:mn>1</mml:mn>
                      </mml:mrow>
                    </mml:math>
                  </inline-formula>
                </td>
                <td align="left" rowspan="1" colspan="1">Drug-drug network DDI</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <inline-formula id="inf36">
                    <mml:math id="m36" overflow="scroll">
                      <mml:mrow>
                        <mml:mi>D</mml:mi>
                        <mml:mn>2</mml:mn>
                      </mml:mrow>
                    </mml:math>
                  </inline-formula>
                </td>
                <td align="left" rowspan="1" colspan="1">Drug-disease network DD and drug-side effect network DSE</td>
              </tr>
              <tr>
                <td rowspan="4" align="left" colspan="1">Semantic graphs</td>
                <td align="left" rowspan="1" colspan="1">
                  <inline-formula id="inf37">
                    <mml:math id="m37" overflow="scroll">
                      <mml:mrow>
                        <mml:mi>D</mml:mi>
                        <mml:mn>3</mml:mn>
                      </mml:mrow>
                    </mml:math>
                  </inline-formula>
                </td>
                <td align="left" rowspan="1" colspan="1">Drug chemical similarity network SD<sub>C</sub>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <inline-formula id="inf38">
                    <mml:math id="m38" overflow="scroll">
                      <mml:mrow>
                        <mml:mi>D</mml:mi>
                        <mml:mn>4</mml:mn>
                      </mml:mrow>
                    </mml:math>
                  </inline-formula>
                </td>
                <td align="left" rowspan="1" colspan="1">Drug ATC similarity network SD<sub>ATC</sub>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <inline-formula id="inf39">
                    <mml:math id="m39" overflow="scroll">
                      <mml:mrow>
                        <mml:mi>D</mml:mi>
                        <mml:mn>5</mml:mn>
                      </mml:mrow>
                    </mml:math>
                  </inline-formula>
                </td>
                <td align="left" rowspan="1" colspan="1">Drug-associated protein sequence similarity network SD<sub>P</sub>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <inline-formula id="inf40">
                    <mml:math id="m40" overflow="scroll">
                      <mml:mrow>
                        <mml:mi>D</mml:mi>
                        <mml:mn>6</mml:mn>
                      </mml:mrow>
                    </mml:math>
                  </inline-formula>
                </td>
                <td align="left" rowspan="1" colspan="1">Three networks based on GO, SD<sub>MF</sub>, SD<sub>CC</sub> and SD<sub>BP</sub>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
    </sec>
    <sec id="s2-4">
      <title>2.4 Selection and weighted fusion networks based on similarity network fusion</title>
      <p>In order to fuse different categories of multi-source data more effectively, we use fusion and splicing methods respectively to achieve drug and target feature representation according to the contribution of the different networks to DTI prediction. Among them, the fusion method of multiple networks in this paper is based on SNF algorithm. The SNF solves a multi-source problem by constructing networks of samples (e.g., drug) for each data type and then efficiently fusing these into one network. The procedure of the algorithm is shown in <xref rid="T3" ref-type="table">Table 3</xref>.</p>
      <table-wrap position="float" id="T3">
        <label>TABLE 3</label>
        <caption>
          <p>The process of six classes of drug networks by using SNF algorithm is described in algorithm 1.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead valign="top">
            <tr>
              <th align="left" rowspan="1" colspan="1">Algorithm 1: SNF_drug</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" rowspan="1" colspan="1">Input:DDI.txt, DD.txt, DSE.txt, SD<sub>C</sub>.txt, SD<sub>P</sub>.txt, SD<sub>ATC</sub>.txt, SD<sub>GO</sub>.txt Output: FuDrug.mat Begin</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">1. Compute the similarity matrix of heterogeneous association matrix based on <inline-formula id="inf41"><mml:math id="m41" overflow="scroll"><mml:mrow><mml:mi>S</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, including DD and DSE: for b 1 to 2 by 1 step do <inline-formula id="inf42"><mml:math id="m42" overflow="scroll"><mml:mrow><mml:mi>S</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>|</mml:mo><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:msub><mml:mi>e</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:msub><mml:mo>∩</mml:mo><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:msub><mml:mi>e</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:msub></mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mo>|</mml:mo><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:msub><mml:mi>e</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:msub><mml:mo>∪</mml:mo><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:msub><mml:mi>e</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:msub></mml:mrow><mml:mo>|</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula> end for;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">2. Calculate edge wights matrix <inline-formula id="inf43"><mml:math id="m43" overflow="scroll"><mml:mrow><mml:msub><mml:mi>W</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, normalized matrix <inline-formula id="inf44"><mml:math id="m44" overflow="scroll"><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and local affinity matrix <inline-formula id="inf45"><mml:math id="m45" overflow="scroll"><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> of each network: for <inline-formula id="inf46"><mml:math id="m46" overflow="scroll"><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:math></inline-formula> 1 to L by 1 step do Compute <inline-formula id="inf47"><mml:math id="m47" overflow="scroll"><mml:mrow><mml:msub><mml:mi>W</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> based on <xref rid="e1" ref-type="disp-formula">Eqs 1</xref>, <xref rid="e2" ref-type="disp-formula">2</xref>; Compute <inline-formula id="inf48"><mml:math id="m48" overflow="scroll"><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> based on <xref rid="e3" ref-type="disp-formula">Eq. 3</xref>; Compute <inline-formula id="inf49"><mml:math id="m49" overflow="scroll"><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> based on <xref rid="e4" ref-type="disp-formula">Eq. 4</xref>; end for;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">3. Each similarity network is updated t times iteratively based on <inline-formula id="inf50"><mml:math id="m50" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>E</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula> : for i 1 to t by 1 step do for <inline-formula id="inf51"><mml:math id="m51" overflow="scroll"><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:math></inline-formula> 1 to L by 1 step do Compute <inline-formula id="inf52"><mml:math id="m52" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>E</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula> based on <xref rid="e5" ref-type="disp-formula">Eq. 5</xref>; end for;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">4. After t iterations, calculating the population state matrix <inline-formula id="inf53"><mml:math id="m53" overflow="scroll"><mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> based on <xref rid="e6" ref-type="disp-formula">Eq. 6</xref>. End.</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Suppose that there are <inline-formula id="inf54"><mml:math id="m54" overflow="scroll"><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:math></inline-formula> drug networks, let <inline-formula id="inf55"><mml:math id="m55" overflow="scroll"><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> represents the adjacency matrix of the drug network<inline-formula id="inf56"><mml:math id="m56" overflow="scroll"><mml:mrow><mml:mi>l</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>1,2</mml:mn><mml:mo>,</mml:mo><mml:mo>⋯</mml:mo><mml:mo>,</mml:mo><mml:mi>L</mml:mi></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>. The matrix element <inline-formula id="inf57"><mml:math id="m57" overflow="scroll"><mml:mrow><mml:msub><mml:mi>W</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> is defined as follows:<disp-formula id="e1"><mml:math id="m58" overflow="scroll"><mml:mrow><mml:msub><mml:mi>W</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mo>−</mml:mo><mml:msup><mml:mi>ρ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>μ</mml:mi><mml:msub><mml:mi>ϵ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math><label>(1)</label></disp-formula>where <inline-formula id="inf58"><mml:math id="m59" overflow="scroll"><mml:mrow><mml:msup><mml:mi>ρ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo></mml:mrow></mml:msub><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>represents the Euclidean distance between drug <inline-formula id="inf59"><mml:math id="m60" overflow="scroll"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula id="inf60"><mml:math id="m61" overflow="scroll"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf61"><mml:math id="m62" overflow="scroll"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> is the vector of similarity between the <inline-formula id="inf62"><mml:math id="m63" overflow="scroll"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:math></inline-formula>-th drug and all the other drugs, <inline-formula id="inf63"><mml:math id="m64" overflow="scroll"><mml:mrow><mml:mi>μ</mml:mi></mml:mrow></mml:math></inline-formula> is a hyperparameter and we recommend setting µ in the range [0.3, 0.8]. Note that while this distance measure works for continuous variables, we recommend using chi-square distances for discrete variables and protocol-based measures for binary variables. <inline-formula id="inf64"><mml:math id="m65" overflow="scroll"><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> is described as follows.<disp-formula id="e2"><mml:math id="m66" overflow="scroll"><mml:mrow><mml:msub><mml:mi>ϵ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>ρ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>ρ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>ρ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>3</mml:mn></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math><label>(2)</label></disp-formula>where <inline-formula id="inf65"><mml:math id="m67" overflow="scroll"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mrow><mml:mo>|</mml:mo><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> represents the neighbors of the drug in the network <inline-formula id="inf66"><mml:math id="m68" overflow="scroll"><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:math></inline-formula>, mean<inline-formula id="inf67"><mml:math id="m69" overflow="scroll"><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>ρ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> is the average value of the distances between <inline-formula id="inf68"><mml:math id="m70" overflow="scroll"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and its neighbors.</p>
      <p>To compute the fused matrix from multiple types of measurements, we need to project multiple data types into the same space. Thus, all data types are normalized by calculating matrix <inline-formula id="inf69"><mml:math id="m71" overflow="scroll"><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>. The normalized matrix <inline-formula id="inf70"><mml:math id="m72" overflow="scroll"><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mi>l</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> is described as follows,<disp-formula id="e3"><mml:math id="m73" overflow="scroll"><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>W</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mo>∑</mml:mo><mml:mrow><mml:mi>a</mml:mi><mml:mo>≠</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>W</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>≠</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math><label>(3)</label></disp-formula>where the matrix <inline-formula id="inf71"><mml:math id="m74" overflow="scroll"><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mi>l</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> is not affected by self-similarity in the diagonal entries and <inline-formula id="inf72"><mml:math id="m75" overflow="scroll"><mml:mrow><mml:msub><mml:mo>∑</mml:mo><mml:mi>j</mml:mi></mml:msub><mml:msub><mml:mi>E</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>.</p>
      <p>Considering that different drugs tend to have different numbers of neighbors, K nearest neighbors (KNN) is used to measure local affinity as:<disp-formula id="e4"><mml:math id="m76" overflow="scroll"><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>W</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>∈</mml:mo><mml:msubsup><mml:mi>N</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>K</mml:mi><mml:mi>N</mml:mi><mml:mi>N</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub><mml:msub><mml:mi>W</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>∈</mml:mo><mml:msubsup><mml:mi>N</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>K</mml:mi><mml:mi>N</mml:mi><mml:mi>N</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>w</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math><label>(4)</label></disp-formula>where <inline-formula id="inf73"><mml:math id="m77" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>N</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>K</mml:mi><mml:mi>N</mml:mi><mml:mi>N</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> represents K neighbors of drug <inline-formula id="inf74"><mml:math id="m78" overflow="scroll"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>.</p>
      <p>After calculating similarity matrixes and local affinity matrixes of drugs under different source data, we iteratively update similarity matrixes as follows:<disp-formula id="e5"><mml:math id="m79" overflow="scroll"><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mo>∑</mml:mo><mml:mrow><mml:mi>b</mml:mi><mml:mo>≠</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>E</mml:mi><mml:mi>b</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>L</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mi>l</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>T</mml:mi></mml:msup><mml:mo>,</mml:mo><mml:mi>l</mml:mi><mml:mo>=</mml:mo><mml:mn>1,2</mml:mn><mml:mo>,</mml:mo><mml:mo>⋯</mml:mo><mml:mo>,</mml:mo><mml:mi>L</mml:mi></mml:mrow></mml:math><label>(5)</label></disp-formula>
</p>
      <p>Finally, we get state matrix <inline-formula id="inf75"><mml:math id="m80" overflow="scroll"><mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mi>G</mml:mi></mml:msup></mml:mrow></mml:math></inline-formula> by calculating the average of matrix <inline-formula id="inf76"><mml:math id="m81" overflow="scroll"><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mi>l</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> after t iterations as follows:<disp-formula id="e6"><mml:math id="m82" overflow="scroll"><mml:mrow><mml:msup><mml:mi>E</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>l</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>L</mml:mi></mml:msubsup><mml:msubsup><mml:mi>E</mml:mi><mml:mi>l</mml:mi><mml:mi>t</mml:mi></mml:msubsup></mml:mrow><mml:mi>L</mml:mi></mml:mfrac></mml:mrow></mml:math><label>(6)</label></disp-formula>
</p>
      <p>According to the contribution of multi-source data of drugs and targets to DTIs prediction, we will adopt three different strategies for data fusion. Detailed description is as follows.</p>
      <sec id="s2-4-1">
        <title>2.4.1 Selective fusion</title>
        <p>Considering the high-noise nature of multi-source data, we measure the contribution of each data source to DTIs prediction. In order to avoid the data with low contribution mixing with high noise in the process of data fusion and affecting the prediction accuracy, the data sources with low contribution are deleted (see Results), and the remaining drug and target data are fused using SNF respectively.</p>
      </sec>
      <sec id="s2-4-2">
        <title>2.4.2 Weighted fusion based on entropy</title>
        <p>The drug or target similarity network calculated by each data source often contains different information. Thus, we compute the nodes’ average entropy to determine each network’s information. For any matrix <inline-formula id="inf77"><mml:math id="m83" overflow="scroll"><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, the entropy of node <inline-formula id="inf78"><mml:math id="m84" overflow="scroll"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> is defined as:<disp-formula id="e7"><mml:math id="m85" overflow="scroll"><mml:mrow><mml:msub><mml:mi>H</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:msub><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mrow><mml:munderover><mml:mstyle displaystyle="true"><mml:mo>∑</mml:mo></mml:mstyle><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>⁡</mml:mo><mml:mi>log</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math><label>(7)</label></disp-formula>
<disp-formula id="e8"><mml:math id="m86" overflow="scroll"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>m</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:msubsup><mml:mi>Σ</mml:mi><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:msubsup><mml:msub><mml:mi>m</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math><label>(8)</label></disp-formula>where <inline-formula id="inf79"><mml:math id="m87" overflow="scroll"><mml:mrow><mml:msub><mml:mi>m</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> represents a item in the matrix <inline-formula id="inf80"><mml:math id="m88" overflow="scroll"><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>l</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>. Finally, we get the average entropy of all rows as:<disp-formula id="e9"><mml:math id="m89" overflow="scroll"><mml:mrow><mml:msub><mml:mi>H</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:munderover><mml:mstyle displaystyle="true"><mml:mo>∑</mml:mo></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:msub><mml:mi>H</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math><label>(9)</label></disp-formula>
</p>
        <p>We take entropy as the weight and update <inline-formula id="inf81"><mml:math id="m90" overflow="scroll"><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>l</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> as follows:<disp-formula id="e10"><mml:math id="m91" overflow="scroll"><mml:mrow><mml:mi>H</mml:mi><mml:msub><mml:mi>W</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mo>×</mml:mo><mml:msub><mml:mi>H</mml:mi><mml:mi>l</mml:mi></mml:msub></mml:mrow></mml:math><label>(10)</label></disp-formula>
</p>
      </sec>
      <sec id="s2-4-3">
        <title>2.4.3 Selective and weighted fusion</title>
        <p>Combine the two strategies above, the data are filtered which is based on the feedback of the classification networks’ combined results in <xref rid="s10" ref-type="sec">Supplementary Table S1</xref> (see <xref rid="s10" ref-type="sec">Supplementary Material</xref>), then similar networks are updated though weighting entropy value of networks.</p>
      </sec>
    </sec>
    <sec id="s2-5">
      <title>2.5 Low dimensional vectors for learning node features</title>
      <p>In this paper, DNGR model is used to learn node features from multi-source networks. It consists of three parts, including random surfing, calculation of Positive Pointwise Mutual Information (PPMI) matrix and feature reduction by Stacked Denoising Auto Encoder (SDAE).</p>
      <sec id="s2-5-1">
        <title>2.5.1 Random surfing</title>
        <p>The random surfing model motivated by the PageRank model used for ranking tasks. The nodes in the network are randomly ordered. For a node, there is a transition matrix <inline-formula id="inf82"><mml:math id="m92" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:math></inline-formula> that captures transition probability between different nodes in a network, where <inline-formula id="inf83"><mml:math id="m93" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mi>r</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> represents the transition probability from <inline-formula id="inf84"><mml:math id="m94" overflow="scroll"><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:math></inline-formula> to <inline-formula id="inf85"><mml:math id="m95" overflow="scroll"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:math></inline-formula>. It considers a random surfing model with restart which introduces a predetermined restart probability at the initial node of each iteration, which can be diagonalized as follow:<disp-formula id="e11"><mml:math id="m96" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="bold-italic">p</mml:mi><mml:mi mathvariant="bold-italic">k</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>α</mml:mi><mml:msub><mml:mi mathvariant="bold-italic">p</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">k</mml:mi><mml:mo>−</mml:mo><mml:mn mathvariant="bold">1</mml:mn></mml:mrow></mml:msub><mml:mi>T</mml:mi><mml:mi>r</mml:mi><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>α</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi mathvariant="bold-italic">p</mml:mi><mml:mn mathvariant="bold">0</mml:mn></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math><label>(11)</label></disp-formula>where <inline-formula id="inf86"><mml:math id="m97" overflow="scroll"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> is the initial 1-hot vector, it said that the <inline-formula id="inf87"><mml:math id="m98" overflow="scroll"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:math></inline-formula>-th item is 1 and all other items is 0. The row vector <inline-formula id="inf88"><mml:math id="m99" overflow="scroll"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, whose <inline-formula id="inf89"><mml:math id="m100" overflow="scroll"><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:math></inline-formula>-th item indicates the probability of reaching the <inline-formula id="inf90"><mml:math id="m101" overflow="scroll"><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:math></inline-formula>-th node after the <inline-formula id="inf91"><mml:math id="m102" overflow="scroll"><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:math></inline-formula> transition. Based on <xref rid="e11" ref-type="disp-formula">Eq. 11</xref>, <inline-formula id="inf92"><mml:math id="m103" overflow="scroll"><mml:mrow><mml:mi>α</mml:mi></mml:mrow></mml:math></inline-formula> is the probability that <inline-formula id="inf93"><mml:math id="m104" overflow="scroll"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:math></inline-formula>-th node will continue the random surfing procedure, and <inline-formula id="inf94"><mml:math id="m105" overflow="scroll"><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>α</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> is the probability that <inline-formula id="inf95"><mml:math id="m106" overflow="scroll"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:math></inline-formula>-th node will back to the original node that restart this procedure. A probabilistic co-occurrence matrix <inline-formula id="inf96"><mml:math id="m107" overflow="scroll"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>O</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> is produced by the accumulation of random walk values in a network where two vertices exist directly or after several jumps.</p>
      </sec>
      <sec id="s2-5-2">
        <title>2.5.2 Positive pointwise mutual information matrix</title>
        <p>In random surfing process, the probabilistic co-occurrence matrix <inline-formula id="inf97"><mml:math id="m108" overflow="scroll"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>O</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> is obtained by summing up the matrices <inline-formula id="inf98"><mml:math id="m109" overflow="scroll"><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:math></inline-formula> generated by the random surfing between two nodes in a network, either directly or after several jumps. Then, we calculate PPMI matrix as follows (<xref rid="B7" ref-type="bibr">Bullinaria and Levy, 2007</xref>):<disp-formula id="e12"><mml:math id="m110" overflow="scroll"><mml:mrow><mml:mi>P</mml:mi><mml:mi>P</mml:mi><mml:mi>M</mml:mi><mml:mi>I</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="italic">log</mml:mi><mml:mfrac><mml:mrow><mml:mi>P</mml:mi><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>×</mml:mo><mml:msub><mml:mo>∑</mml:mo><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mo>∑</mml:mo><mml:mi>j</mml:mi></mml:msub><mml:mi>P</mml:mi><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mo>∑</mml:mo><mml:mi>i</mml:mi></mml:msub><mml:mi>P</mml:mi><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>×</mml:mo><mml:msub><mml:mo>∑</mml:mo><mml:mi>j</mml:mi></mml:msub><mml:mi>P</mml:mi><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math><label>(12)</label></disp-formula>where <inline-formula id="inf99"><mml:math id="m111" overflow="scroll"><mml:mrow><mml:msub><mml:mo>∑</mml:mo><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mo>∑</mml:mo><mml:mi>j</mml:mi></mml:msub><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>O</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> represents the sum of all the elements of the matrix <inline-formula id="inf100"><mml:math id="m112" overflow="scroll"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>O</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf101"><mml:math id="m113" overflow="scroll"><mml:mrow><mml:msub><mml:mo>∑</mml:mo><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula id="inf102"><mml:math id="m114" overflow="scroll"><mml:mrow><mml:msub><mml:mo>∑</mml:mo><mml:mi>j</mml:mi></mml:msub><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> represent the sum of row elements values and column elements values respectively.</p>
      </sec>
      <sec id="s2-5-3">
        <title>2.5.3 Stacked denoising auto encoder</title>
        <p>Finally, the PPMI matrix is used as the input feature <inline-formula id="inf103"><mml:math id="m115" overflow="scroll"><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:math></inline-formula> of SDAE, we get high quality low-dimensional vector representations for nodes from the PPMI matrix. The idea of SDAE is to stack multiple denoising autoencoder (DAE) together to form a deep framework. The SDAE uses layer-by-layer greed training, unsupervised training is carried out on each auto coding layer separately, to minimize the error between the input and the reconstruction results. For each hidden layer, the DAE randomly sets the value of the input node being 0 to add noise to the input data in the input layer to prevent overfitting. For example, for a network, the input matrix PPMI of SDAE is 732*732 dimensions, and the output feature dimension is set by yourself. In this paper, the feature dimension is set as 100 dimensions for a drug or target. The SDAE model minimizes the regularized problem and tackles reconstruction error (<xref rid="B41" ref-type="bibr">Zeng et al., 2020</xref>), defined as follows:<disp-formula id="e13"><mml:math id="m116" overflow="scroll"><mml:mrow><mml:munder><mml:mi>min</mml:mi><mml:mrow><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mi>W</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mi>y</mml:mi></mml:msub></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:msub><mml:mi>b</mml:mi><mml:mi>y</mml:mi></mml:msub></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:munder><mml:mo>∥</mml:mo><mml:mi>x</mml:mi><mml:mo>−</mml:mo><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:msubsup><mml:mo>∥</mml:mo><mml:mi>F</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:mi>λ</mml:mi><mml:mrow><mml:munder><mml:mstyle displaystyle="true"><mml:mo>∑</mml:mo></mml:mstyle><mml:mi>y</mml:mi></mml:munder><mml:mrow><mml:mo>∥</mml:mo><mml:mi>W</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mi>y</mml:mi></mml:msub><mml:msubsup><mml:mo>∥</mml:mo><mml:mi>F</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math><label>(13)</label></disp-formula>where <inline-formula id="inf104"><mml:math id="m117" overflow="scroll"><mml:mrow><mml:mi>W</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mi>y</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> is weight matrix, and <inline-formula id="inf105"><mml:math id="m118" overflow="scroll"><mml:mrow><mml:msub><mml:mi>b</mml:mi><mml:mi>y</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> is the bias vector of layer <inline-formula id="inf106"><mml:math id="m119" overflow="scroll"><mml:mrow><mml:mi>y</mml:mi><mml:mo>∈</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>1,2</mml:mn><mml:mo>,</mml:mo><mml:mo>⋯</mml:mo><mml:mo>,</mml:mo><mml:mi>Y</mml:mi></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>. <inline-formula id="inf107"><mml:math id="m120" overflow="scroll"><mml:mrow><mml:mi>Y</mml:mi></mml:mrow></mml:math></inline-formula> is the number of layers. <inline-formula id="inf108"><mml:math id="m121" overflow="scroll"><mml:mrow><mml:mi>λ</mml:mi></mml:mrow></mml:math></inline-formula> is hyperparameter and <inline-formula id="inf109"><mml:math id="m122" overflow="scroll"><mml:mrow><mml:mo>‖</mml:mo><mml:mo>•</mml:mo><mml:mo>‖</mml:mo></mml:mrow></mml:math></inline-formula> denotes the Frobenius norm.</p>
      </sec>
    </sec>
    <sec id="s2-6">
      <title>2.6 Drug target interactions prediction based on LightGBM</title>
      <p>LightGBM which is an efficient implementation of Gradient Boosting Decision Tree (<xref rid="B13" ref-type="bibr">Friedman, 2001</xref>) (GBDT) is proposed by Microsoft. GBDT is a decision tree-based algorithm, it contains multiple based classifiers. The based classifier of each layer is based on the residual of the training data of the based classifier of the previous layer. According to the residual of a layer, the gradient is calculated to fit the regression tree. Finally, using the principle of addition model, all the trained based classifier are added and integrated into the final decision. Compared to the traditional GBDT model, LightGBM improves the efficiency of training data and the accuracy of DTIs prediction.</p>
    </sec>
  </sec>
  <sec id="s3">
    <title>3 Results</title>
    <sec id="s3-1">
      <title>3.1 Performance analysis of drug target prediction based on combined multiple networks</title>
      <p>In order to measure the DTIs prediction effects of different drugs and target data sources of different classes, pairwise combinations of different drug data and target data are conducted to calculate the DTIs prediction performance. If a type of network contains more than one, we have two ways to learn the features of nodes in the net-work: 1) Multiple networks are fused using SNF, and low-dimensional representations of nodes of the fused network are learned using DNGR; 2) Low-dimensional representations of nodes of each network are learned using DNGR, and then the features of nodes are spliced for multiple networks.</p>
      <p>*<inline-formula id="inf110"><mml:math id="m123" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>4</mml:mn><mml:mi>S</mml:mi></mml:mrow></mml:math></inline-formula> means the fourth category <inline-formula id="inf111"><mml:math id="m124" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:math></inline-formula> including three networks select splicing method. <inline-formula id="inf112"><mml:math id="m125" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn><mml:mi>F</mml:mi></mml:mrow></mml:math></inline-formula> and <inline-formula id="inf113"><mml:math id="m126" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>6</mml:mn><mml:mi>F</mml:mi></mml:mrow></mml:math></inline-formula> mean the second and sixth category of drugs, including multiple networks that select fusing method.</p>
      <p>Considering that the category networks of drugs <inline-formula id="inf114"><mml:math id="m127" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf115"><mml:math id="m128" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>6</mml:mn></mml:mrow></mml:math></inline-formula> and that of target <inline-formula id="inf116"><mml:math id="m129" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:math></inline-formula>, we used the above two methods respectively to compare the area under the receiver operating characteristic curve (AUROC) of DTIs combined with different data (<xref rid="F2" ref-type="fig">Figures 2A,B</xref>). It is shown that the contribution of drugs <inline-formula id="inf117"><mml:math id="m130" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula id="inf118"><mml:math id="m131" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>, targets <inline-formula id="inf119"><mml:math id="m132" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula id="inf120"><mml:math id="m133" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula> to DTIs prediction is much lower than other data. Also, it is found that the fusion method has advantages in DTIs prediction for drugs and that of the splicing method for target (<xref rid="F2" ref-type="fig">Figures 2A,B</xref>). According to the comprehensive analysis of <xref rid="F2" ref-type="fig">Figure 2</xref>, we come to two conclusions about drugs based on the SNF fusion method as follows:<list list-type="simple"><list-item><p>(1) <inline-formula id="inf121"><mml:math id="m134" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>3</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf122"><mml:math id="m135" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula id="inf123"><mml:math id="m136" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>6</mml:mn></mml:mrow></mml:math></inline-formula> of drugs, <inline-formula id="inf124"><mml:math id="m137" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>3</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula id="inf125"><mml:math id="m138" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:math></inline-formula> of targets have a greater influence on the final results, while <inline-formula id="inf126"><mml:math id="m139" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf127"><mml:math id="m140" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula id="inf128"><mml:math id="m141" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf129"><mml:math id="m142" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula> which are topological graphs may have unavoidable noise that will affect the accuracy of DTIs prediction.</p></list-item><list-item><p>(2) Fused networks that combine multiple networks in <inline-formula id="inf130"><mml:math id="m143" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula id="inf131"><mml:math id="m144" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>6</mml:mn></mml:mrow></mml:math></inline-formula> of drugs have the better performance than that of splicing; while splicing the feature vectors of nodes in each network is slightly better than fusing network in <inline-formula id="inf132"><mml:math id="m145" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:math></inline-formula>, as shown as in <xref rid="F2" ref-type="fig">Figure 2B</xref>.</p></list-item></list>
</p>
      <fig position="float" id="F2">
        <label>FIGURE 2</label>
        <caption>
          <p>Comparison of DTI prediction accuracy (AUROC) under different drug and target data combinations. It describes the DTIs prediction of six categories of drugs and four categories of targets combinations. <bold>(A)</bold> The DTIs prediction of drugs <inline-formula id="inf133"><mml:math id="m146" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1,3,4,5</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> which contains one network combine all target class networks and target <inline-formula id="inf134"><mml:math id="m147" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1,2,3</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> which contain one network combine all drug class networks; <bold>(B)</bold> the DTIs prediction of drugs <inline-formula id="inf135"><mml:math id="m148" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2,6</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and target <inline-formula id="inf136"><mml:math id="m149" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>4</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> with fusion and splicing respectively.</p>
        </caption>
        <graphic xlink:href="fphar-13-1009996-g002" position="float"/>
      </fig>
      <p>Therefore, in the subsequent analysis, fusion and splicing methods are used for <inline-formula id="inf137"><mml:math id="m150" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf138"><mml:math id="m151" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>6</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula id="inf139"><mml:math id="m152" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:math></inline-formula> respectively. Based on the above two conclusions, we consider selective and weighted fusion (see Materials and Methods) to complete the DTIs prediction.</p>
    </sec>
    <sec id="s3-2">
      <title>3.2 Comparison of drug target interactions prediction performance under different fusion methods</title>
      <p>Through the comprehensive analysis of <xref rid="F2" ref-type="fig">Figure 2</xref>, we can see that the AUROC is lower based on <inline-formula id="inf140"><mml:math id="m153" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf141"><mml:math id="m154" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf142"><mml:math id="m155" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula id="inf143"><mml:math id="m156" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula> in the DTI prediction than others. Although there are better results when <inline-formula id="inf144"><mml:math id="m157" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf145"><mml:math id="m158" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula> combines with <inline-formula id="inf146"><mml:math id="m159" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>3</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula id="inf147"><mml:math id="m160" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:math></inline-formula>, and <inline-formula id="inf148"><mml:math id="m161" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf149"><mml:math id="m162" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula> combines <inline-formula id="inf150"><mml:math id="m163" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>3</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf151"><mml:math id="m164" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula id="inf152"><mml:math id="m165" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>6</mml:mn><mml:mi>F</mml:mi></mml:mrow></mml:math></inline-formula>, this may be due to the high contribution of <inline-formula id="inf153"><mml:math id="m166" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>3</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf154"><mml:math id="m167" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf155"><mml:math id="m168" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>3</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf156"><mml:math id="m169" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula id="inf157"><mml:math id="m170" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>6</mml:mn><mml:mi>F</mml:mi></mml:mrow></mml:math></inline-formula> to the final results. Therefore, we think that <inline-formula id="inf158"><mml:math id="m171" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf159"><mml:math id="m172" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf160"><mml:math id="m173" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula id="inf161"><mml:math id="m174" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula> provide less contribution to DTIs prediction and may introduce high noise.</p>
      <p>According to the above results, we complete network fusion with different strategies. For high noise data, different filtering or weighting strategies are used and ablation experiments are performed. Then low-dimensional feature vectors of drugs and targets are learned based on DNGR. Finally, LightGBM was used to obtain a good prediction effect based on selective and weighted strategy, that is, AUROC and AUPR were 0.982.</p>
      <sec id="s3-2-1">
        <title>3.2.1 Selective fusion</title>
        <p>To reduce the effect of high noise, we simply filter <inline-formula id="inf162"><mml:math id="m175" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf163"><mml:math id="m176" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf164"><mml:math id="m177" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula id="inf165"><mml:math id="m178" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>. <xref rid="T4" ref-type="table">Table 4</xref> shows that selective fusion has better effects in two indexes, AUROC and the area under the recall versus precision curve (AUPR) compared to total data fusion. It is shown that reducing the introduction of high noise is indeed helpful in improving the prediction performance. Also, it is found that the optimal combination fusion is obtained when only <inline-formula id="inf166"><mml:math id="m179" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf167"><mml:math id="m180" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula> of drugs are deleted. It shows that although deleting noisy data can improve performance, simple deletion can also cause some information to be lost.</p>
        <table-wrap position="float" id="T4">
          <label>TABLE 4</label>
          <caption>
            <p>Prediction performance of selective fusion. For ease of description, abbreviations in the model are expressed as follows.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead valign="top">
              <tr>
                <th align="left" rowspan="1" colspan="1">Model</th>
                <th align="left" rowspan="1" colspan="1">AUROC</th>
                <th align="left" rowspan="1" colspan="1">AUPR</th>
              </tr>
            </thead>
            <tbody valign="top">
              <tr>
                <td align="left" rowspan="1" colspan="1">DF_TFS</td>
                <td align="left" rowspan="1" colspan="1">0.903</td>
                <td align="left" rowspan="1" colspan="1">0.908</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">DE_D125_DF_TFS</td>
                <td align="left" rowspan="1" colspan="1">0.918</td>
                <td align="left" rowspan="1" colspan="1">0.923</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">DE_D12_T12_DF_TS</td>
                <td align="left" rowspan="1" colspan="1">0.924</td>
                <td align="left" rowspan="1" colspan="1">0.933</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>DE_D12_DF_TFS</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>0.942</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>0.950</bold>
                </td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">WEC_DF_TFS</td>
                <td align="left" rowspan="1" colspan="1">0.903</td>
                <td align="left" rowspan="1" colspan="1">0.904</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>WE_DF_TFS</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>0.904</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>0.905</bold>
                </td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
                  <bold>DE_D12_WE_DF_TFP</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>0.982</bold>
                </td>
                <td align="left" rowspan="1" colspan="1">
                  <bold>0.982</bold>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>*D and T are drug and target; F and S are fusion and splicing; DE represents delete; A D or T followed by numbers indicates what kinds of data is deleted. The abbreviations WE and WEC represent unclassified network-based entropy and classified network entropy respectively.</p>
            </fn>
            <fn>
              <p>DE_D12_DF_TFS means that the first class of the drug is deleted, and the remaining drugs are fully fused, and the first, second and third classes of the target are fused to learn the features and then spliced with the fourth class.</p>
            </fn>
            <fn>
              <p>WE_DF_TFS means represents the entropy weighting of all the networks of the drug and the target, and all the networks of the drug are fused, and the three types of networks before the target are fused to learn features, and then they are spliced with the fourth type of network.</p>
            </fn>
            <fn>
              <p>DE_D12_WE_DF_TFP represents the synthesis of the first two bold methods, that is, the first type of drug network is deleted, all the networks are entropy-weighted, and the drug network is fully fused, and the first three types of target networks are fused to learn features, and then spliced with the fourth type of network.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="s3-2-2">
        <title>3.2.2 Weighted entropy fusion</title>
        <p>Considering the fact that different data sources may provide different contributions to DTIs prediction, simple deletion may cause information loss, so a weighted fusion of different data sources is carried out. In weighted fusion, we use entropy to evaluate the weighted value of each network during fusion (see Materials and methods). For calculating the entropy of networks, we consider two cases: One is the unclassified networks, and the other is the classified networks. The unclassified networks calculate the entropy of each network by SoftMax, normalized all values of the entropy, and weighted every network before fusing. For the classified network, the difference is that the normalization is based on the classified networks, that is, two or more networks in the classified network contains have to be multiplied by the same weight value. We can see that there is little difference between the two methods of weighted fusion. However, compared with directly deleting the data with low predictive performance, the method based on weighted fusion is significantly lower than the method based on selective fusion.</p>
      </sec>
      <sec id="s3-2-3">
        <title>3.2.3 Selective weighted fusion</title>
        <p>Combining the advantages of selection and weighting strategies, a selective and weighted entropy fusion strategy is used. After deleting <inline-formula id="inf168"><mml:math id="m181" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="inf169"><mml:math id="m182" overflow="scroll"><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula> and performing weighted fusion on the remaining data, it is found that it has better performance in DTIs than only selective or only weighted fusion (<xref rid="T4" ref-type="table">Table 4</xref>).</p>
      </sec>
    </sec>
    <sec id="s3-3">
      <title>3.3 High performance of EFMSDTI</title>
      <p>Based on the ablation experimental, the strategy of selective weighted fusion is used to predict DTIs, named EFMSDTI. To evaluate the performance of EFMSDTI, four previous state-of-the-art methods are used for comparison. In a 5-fold cross-validation, 20% of the positive and negative samples are randomly selected as the test set, and 80% of the drug-target pairs are used as the training set. As the <xref rid="T5" ref-type="table">Table 5</xref>, EFMSDTI, which has the highest AUROC and AUPR, outperforms four previous state-of-the-art methods: NEFTP, NeoDTI, deepDTnet, DTINet. A brief description of these methods is as follows:</p>
      <table-wrap position="float" id="T5">
        <label>TABLE 5</label>
        <caption>
          <p>Comparison of EFMSDTI with other state-of-the-art methods for DTIs prediction.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead valign="top">
            <tr>
              <th align="left" rowspan="1" colspan="1">Model</th>
              <th align="left" rowspan="1" colspan="1">AUROC</th>
              <th align="left" rowspan="1" colspan="1">AUPR</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" rowspan="1" colspan="1">EFMSDTI</td>
              <td align="left" rowspan="1" colspan="1">
                <bold>0.982</bold>
              </td>
              <td align="left" rowspan="1" colspan="1">
                <bold>0.982</bold>
              </td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">NEDTP <xref rid="B2" ref-type="bibr">An and Yu, (2021</xref>)</td>
              <td align="left" rowspan="1" colspan="1">0.971</td>
              <td align="left" rowspan="1" colspan="1">0.967</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">deepDTnet <xref rid="B41" ref-type="bibr">Zeng et al. (2020</xref>)</td>
              <td align="left" rowspan="1" colspan="1">0.963</td>
              <td align="left" rowspan="1" colspan="1">0.969</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">NeoDTI <xref rid="B29" ref-type="bibr">Wan et al. (2018</xref>)</td>
              <td align="left" rowspan="1" colspan="1">0.97</td>
              <td align="left" rowspan="1" colspan="1">0.91</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">DTINet <xref rid="B20" ref-type="bibr">Luo et al. (2017</xref>)</td>
              <td align="left" rowspan="1" colspan="1">0.932</td>
              <td align="left" rowspan="1" colspan="1">0.943</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <sec id="s3-3-1">
        <title>3.3.1 NEFTP</title>
        <p>A heterogeneous network embedding framework for predicting similarity-based drug-target interactions was performed, which builds a similarity network based on 15 heterogeneous information networks, and applies a random walk to extract the information of nodes in the network and learns low-dimensional vectors. Finally, the classifier predicts DTIs (<xref rid="B2" ref-type="bibr">An and Yu, 2021</xref>). It learns node features by treating the random walk paths of different networks equally, but the contributions of different networks are different.</p>
      </sec>
      <sec id="s3-3-2">
        <title>3.3.2 NeoDTI</title>
        <p>Integration of neighbor information from a heterogeneous network for discovering new drug-target interactions develop a new nonlinear end-to-end learning model (<xref rid="B29" ref-type="bibr">Wan et al., 2018</xref>). The model integrates various information from heterogeneous network data and automatically learns representations that preserve drug and target topologies to facilitate DTI prediction.It focuses on the topological information of drugs and targets, and the collection of feature information is not enough, only drug structure similarity and target sequence similarity. But the characteristic information of drug and target is not limited to these two.</p>
      </sec>
      <sec id="s3-3-3">
        <title>3.3.3 deepDTnet</title>
        <p>Target identification among known drugs by deep learning from heterogeneous networks (<xref rid="B41" ref-type="bibr">Zeng et al., 2020</xref>) was implemented, which collects 15 information networks to learn the feature vectors of each node in each network, and inputs the PU prediction model to predict DTIs after splicing 15 feature vectors. Similarly, the model treats multi-source data equally, but the contribution of each information network is different.</p>
      </sec>
      <sec id="s3-3-4">
        <title>3.3.4 DTINet</title>
        <p>A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information was implemented, which integrates multi-network information and learns node features through compact feature learning algorithm, and finally inputs DTIs in PU learning. Although it integrates multi-network information, it does not consider the in-depth study of multi-network information fusion.</p>
      </sec>
    </sec>
    <sec id="s3-4">
      <title>3.4 Validation of the top-ranked predictions</title>
      <p>In order to further analyze the performance of EFMSDTI method to identify DTIs, the top-ranked predictions are verified. We select the top 1000 prediction DTIs for each fold, and merge the 5-folds by averaging. The top 1000 prediction DTIs are analyzed in our analysis. As shown in <xref rid="F3" ref-type="fig">Figure 3</xref>, 990 of the top 1000 DTIs are known DTIs. The top 25, 50, 200 and 500 prediction results are known DTIs. Based on the predicted score of the model, the drug-target pairs that do not interact in known DTIs are considered to be novel DTIs according to rank of the predicted value in the top 1000 samples. Ten DTIs in the first 1000 prediction results that are not verified in <xref rid="T6" ref-type="table">Table 6</xref>.</p>
      <fig position="float" id="F3">
        <label>FIGURE 3</label>
        <caption>
          <p>The number of DTIs that were verified to exist in the top 1000 prediction results.</p>
        </caption>
        <graphic xlink:href="fphar-13-1009996-g003" position="float"/>
      </fig>
      <table-wrap position="float" id="T6">
        <label>TABLE 6</label>
        <caption>
          <p>The 10 unverified DTIs out of the top 1000 prediction results.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead valign="top">
            <tr>
              <th align="left" rowspan="1" colspan="1">DTI’s ranking in the top 1000 predictions</th>
              <th align="left" rowspan="1" colspan="1">Drug</th>
              <th align="left" rowspan="1" colspan="1">Target</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" rowspan="1" colspan="1">922nd</td>
              <td align="left" rowspan="1" colspan="1">DB08882:Linagliptin</td>
              <td align="left" rowspan="1" colspan="1">2934:GSN</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">953rd</td>
              <td align="left" rowspan="1" colspan="1">DB00612:Bisoprolol</td>
              <td align="left" rowspan="1" colspan="1">3283:HSD3B1</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">963rd</td>
              <td align="left" rowspan="1" colspan="1">DB08896:Regorafenib</td>
              <td align="left" rowspan="1" colspan="1">9453:GGPS1</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">991st</td>
              <td align="left" rowspan="1" colspan="1">DB00606:Cyclothiazide</td>
              <td align="left" rowspan="1" colspan="1">4698:NDUFA5</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">993rd</td>
              <td align="left" rowspan="1" colspan="1">DB00602:Ivermectin</td>
              <td align="left" rowspan="1" colspan="1">834:CASP1</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">994th</td>
              <td align="left" rowspan="1" colspan="1">DB01594:Cinolazepam</td>
              <td align="left" rowspan="1" colspan="1">378:ARF4</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">995th</td>
              <td align="left" rowspan="1" colspan="1">DB06204:Tapentadol</td>
              <td align="left" rowspan="1" colspan="1">55825:PECR</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">997th</td>
              <td align="left" rowspan="1" colspan="1">DB00312:Pentobarbital</td>
              <td align="left" rowspan="1" colspan="1">4326:MMP17</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">998th</td>
              <td align="left" rowspan="1" colspan="1">DB01364:Ephedrine</td>
              <td align="left" rowspan="1" colspan="1">4507:MTAP</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">999th</td>
              <td align="left" rowspan="1" colspan="1">DB00459:Acitretin</td>
              <td align="left" rowspan="1" colspan="1">10606:PAICS</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>There were 10 sets of drug-target interactions in the first 1000 prediction results that were not verified in <xref rid="T6" ref-type="table">Table 6</xref>. These DTIs are considered to be potential drug-target interaction. Diseases can be treated with certain drugs, and these drugs are related to the disease. We’re going to test it from different angles. Disease can be caused by the abnormal expression of certain proteins, so this protein is associated with disease. As a result, drugs and targets that share the same disease are thought to be more likely to interact (<xref rid="B2" ref-type="bibr">An and Yu, 2021</xref>). The pair of bisoprolol (drug) and HSD3B1 (target) was one of the novel DTIs identified. The HSD3B1 is related to Hypertensive disease and other diseases. Bisoprolol also appears to have effect on this disease: Hypertensive disease. There is also support for drug-target interactions in the database. Ivermectin and caspase-1 (CASP1) was one of the novel DTIs identified. The target prediction module of drug in CHEMBL database was confirmed to be related to caspase-1 (<xref rid="B6" ref-type="bibr">Bosc et al., 2019</xref>).</p>
    </sec>
  </sec>
  <sec id="s4">
    <title>4 Discussion</title>
    <p>By analyzing and comparing the results of several experiments, we continuously adjust and optimize the prediction model. The results are analyzed and explained, and the optimal model, named EFMSDTI, is obtained based on the currently used data set. The procedure of EFMSDTI is the selective weighted fusing data, extracting the low-dimensional features of drugs and targets, and predicting DTIs using the LightGBM framework. The AUROC value of our final prediction result reached 0.982, which has better performance than several state-of-the-art algorithms.</p>
    <p>DTIs prediction requires more accurate analysis of multi-source data of drugs and targets. Multi-source data can improve more comprehensive information than a single data. However, at the same time, multiple data sources may also bring some noise, so the data processing of multiple-source data is essential. Therefore, considering the contribution of different data, an effective fusion method named EFMSDTI is proposed. The result of the comprehensive analysis shows a higher performance of EFMSDTI. Moreover, through the concept of class network, we also found a new angle of the fusion method. In this paper, we use the popular fusion strategies and entropy-based weighted method to improve the prediction accuracy. The multi-source data used in this paper included nine sources for the drugs and six for the targets. According to current studies (<xref rid="B29" ref-type="bibr">Wan et al., 2018</xref>; <xref rid="B41" ref-type="bibr">Zeng et al., 2020</xref>), data sources for drugs and targets are not limited to this, such as drug-induced gene expression profiles, drug pathways profiles, and so on. In the future, more data sources for drugs and targets will be studied to complement the rich-ness of drugs and targets with multiple networks, and to further confirm our strategy’s robustness. The fused network uses the graph embedding method of DNGR to extract high-quality low-dimensional features in this paper. Currently, there are many other methods to extract features, which may also improve the model’s prediction accuracy.</p>
    <p>In this paper, we manually decide the weighted measure according to the test result metric AUROC, which has certain empiricism and is not a perfect weighting for the results. At present, the most popular mechanism is called attention mechanism, which uses machine self-learning to adjust the weighted value of features during the learning process. The mechanism of self-learning by results will also be the content of future research.</p>
  </sec>
</body>
<back>
  <ack>
    <p>I would like to thank the following teachers for their guidance and help in writing the manuscript and completing the experiment. At the same time, many thanks to editors and reviewers for their suggestions.</p>
  </ack>
  <sec sec-type="data-availability" id="s5">
    <title>Data availability statement</title>
    <p>The original contributions presented in the study are included in the article/<xref rid="s10" ref-type="sec">Supplementary Material</xref>, further inquiries can be directed to the corresponding author.</p>
  </sec>
  <sec id="s6">
    <title>Author contributions</title>
    <p>YZ conceived the idea and prepared the experimental data. MW and YZ debugged the code, conducted the experiments, interpreted the results and wrote and edited the manuscript. SW and WC advised the study and reviewed the manuscript.</p>
  </sec>
  <sec id="s7">
    <title>Funding</title>
    <p>This work is supported by the National Natural Science Foundation of China (61902430, 61873281, 61972226).</p>
  </sec>
  <sec sec-type="COI-statement" id="s8">
    <title>Conflict of interest</title>
    <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
  </sec>
  <sec sec-type="disclaimer" id="s9">
    <title>Publisher’s note</title>
    <p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
  </sec>
  <sec id="s10">
    <title>Supplementary material</title>
    <p>The Supplementary Material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2022.1009996/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fphar.2022.1009996/full#supplementary-material</ext-link>
</p>
    <supplementary-material id="SM1" position="float" content-type="local-data">
      <media xlink:href="Table2.XLSX">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="SM2" position="float" content-type="local-data">
      <media xlink:href="Table1.XLSX">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <ref-list>
    <title>References</title>
    <ref id="B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbasi</surname><given-names>K.</given-names></name><name><surname>Razzaghi</surname><given-names>P.</given-names></name><name><surname>Poso</surname><given-names>A.</given-names></name><name><surname>Ghanbari-Ara</surname><given-names>S.</given-names></name><name><surname>Masoudi-Nejad</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Deep learning in drug target interaction prediction: Current and future perspectives.</article-title>
<source>Curr. Med. Chem.</source>
<volume>28</volume>, <fpage>2100</fpage>–<lpage>2113</lpage>. <pub-id pub-id-type="doi">10.2174/0929867327666200907141016</pub-id>
</mixed-citation>
    </ref>
    <ref id="B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>Q.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name></person-group> (<year>2021</year>). <article-title>A heterogeneous network embedding framework for predicting similarity-based drug-target interactions</article-title>. <source>Brief. Bioinform.</source>
<volume>22</volume>, <fpage>bbab275</fpage>. <pub-id pub-id-type="doi">10.1093/bib/bbab275</pub-id>
<pub-id pub-id-type="pmid">34373895</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avorn</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>The $2.6 billion pill--methodologic and policy considerations</article-title>. <source>N. Engl. J. Med.</source>
<volume>372</volume>, <fpage>1877</fpage>–<lpage>1879</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMp1500848</pub-id>
<pub-id pub-id-type="pmid">25970049</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagherian</surname><given-names>M.</given-names></name><name><surname>Sabeti</surname><given-names>E.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Sartor</surname><given-names>M. A.</given-names></name><name><surname>Nikolovska-Coleska</surname><given-names>Z.</given-names></name><name><surname>Najarian</surname><given-names>K.</given-names></name></person-group> (<year>2021</year>). <article-title>Machine learning approaches and databases for prediction of drug-target interaction: A survey paper</article-title>. <source>Brief. Bioinform.</source>
<volume>22</volume>, <fpage>247</fpage>–<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1093/bib/bbz157</pub-id>
<pub-id pub-id-type="pmid">31950972</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bleakley</surname><given-names>K.</given-names></name><name><surname>Yamanishi</surname><given-names>Y.</given-names></name></person-group> (<year>2009</year>). <article-title>Supervised prediction of drug-target interactions using bipartite local models</article-title>. <source>Bioinformatics</source>
<volume>25</volume>, <fpage>2397</fpage>–<lpage>2403</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btp433</pub-id>
<pub-id pub-id-type="pmid">19605421</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosc</surname><given-names>N.</given-names></name><name><surname>Atkinson</surname><given-names>F.</given-names></name><name><surname>Felix</surname><given-names>E.</given-names></name><name><surname>Gaulton</surname><given-names>A.</given-names></name><name><surname>Hersey</surname><given-names>A.</given-names></name><name><surname>Leach</surname><given-names>A. R.</given-names></name></person-group> (<year>2019</year>). <article-title>Large scale comparison of QSAR and conformal prediction methods and their applications in drug discovery</article-title>. <source>J. Cheminform.</source>
<volume>11</volume>, <fpage>4</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1186/s13321-018-0325-4</pub-id>
<pub-id pub-id-type="pmid">30631996</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullinaria</surname><given-names>J. A.</given-names></name><name><surname>Levy</surname><given-names>J. P.</given-names></name></person-group> (<year>2007</year>). <article-title>Extracting semantic representations from word co-occurrence statistics: A computational study</article-title>. <source>Behav. Res. Methods</source>
<volume>39</volume> (<issue>3</issue>), <fpage>510</fpage>–<lpage>526</lpage>. <pub-id pub-id-type="doi">10.3758/bf03193020</pub-id>
<pub-id pub-id-type="pmid">17958162</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buza</surname><given-names>K.</given-names></name><name><surname>Peška</surname><given-names>L.</given-names></name></person-group> (<year>2017</year>). <article-title>Drug–target interaction prediction with Bipartite Local Models and hubness-aware regression</article-title>. <source>Neurocomputing</source>
<volume>260</volume>, <fpage>284</fpage>–<lpage>293</lpage>. <pub-id pub-id-type="doi">10.1016/j.neucom.2017.04.055</pub-id>
</mixed-citation>
    </ref>
    <ref id="B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>F.</given-names></name><name><surname>Desai</surname><given-names>R. J.</given-names></name><name><surname>Handy</surname><given-names>D. E.</given-names></name><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Loscalzo</surname><given-names>J.</given-names></name><name><surname>Barabasi</surname><given-names>A. L.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Network-based approach to prediction and population-based validation of <italic>in silico</italic> drug repurposing</article-title>. <source>Nat. Commun.</source>
<volume>9</volume>, <fpage>2691</fpage>–<lpage>2712</lpage>. <pub-id pub-id-type="doi">10.1038/s41467-018-05116-5</pub-id>
<pub-id pub-id-type="pmid">30002366</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Prediction of polypharmacological profiles of drugs by the integration of chemical, side effect, and therapeutic space</article-title>. <source>J. Chem. Inf. Model.</source>
<volume>53</volume>, <fpage>753</fpage>–<lpage>762</lpage>. <pub-id pub-id-type="doi">10.1021/ci400010x</pub-id>
<pub-id pub-id-type="pmid">23527559</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>Y.</given-names></name><name><surname>Kaushik</surname><given-names>A. C.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Shan</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>DTI-CDF: A cascade deep forest model towards the prediction of drug-target interactions based on hybrid features.</article-title>
<source>Brief. Bioinform.</source>
<volume>22</volume>, <fpage>451</fpage>–<lpage>462</lpage>. <pub-id pub-id-type="doi">10.1093/bib/bbz152</pub-id>
<pub-id pub-id-type="pmid">31885041</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ezzat</surname><given-names>A.</given-names></name><name><surname>Wu</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>X. L.</given-names></name><name><surname>Kwoh</surname><given-names>C. K.</given-names></name></person-group> (<year>2019</year>). <article-title>Computational prediction of drug-target interactions using chemogenomic approaches: An empirical survey</article-title>. <source>Brief. Bioinform.</source>
<volume>20</volume>, <fpage>1337</fpage>–<lpage>1357</lpage>. <pub-id pub-id-type="doi">10.1093/bib/bby002</pub-id>
<pub-id pub-id-type="pmid">29377981</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>J. H.</given-names></name></person-group> (<year>2001</year>). <article-title>Greedy function approximation: A gradient boosting machine</article-title>. <source>Ann. Stat.</source>
<volume>29</volume>, <fpage>1189</fpage>–<lpage>1232</lpage>. <pub-id pub-id-type="doi">10.1214/aos/1013203451</pub-id>
</mixed-citation>
    </ref>
    <ref id="B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaulton</surname><given-names>A.</given-names></name><name><surname>Bellis</surname><given-names>L. J.</given-names></name><name><surname>Bento</surname><given-names>A. P.</given-names></name><name><surname>Chambers</surname><given-names>J.</given-names></name><name><surname>Davies</surname><given-names>M.</given-names></name><name><surname>Hersey</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>ChEMBL: A large-scale bioactivity database for drug discovery</article-title>. <source>Nucleic Acids Res.</source>
<volume>40</volume>, <fpage>D1100</fpage>–<lpage>D1107</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkr777</pub-id>
<pub-id pub-id-type="pmid">21948594</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez-Boussard</surname><given-names>T.</given-names></name><name><surname>Whirl-Carrillo</surname><given-names>M.</given-names></name><name><surname>Hebert</surname><given-names>J. M.</given-names></name><name><surname>Gong</surname><given-names>L.</given-names></name><name><surname>Owen</surname><given-names>R.</given-names></name><name><surname>Gong</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>The pharmacogenetics and pharmacogenomics knowledge base: Accentuating the knowledge</article-title>. <source>Nucleic Acids Res.</source>
<volume>36</volume>, <fpage>D913</fpage>–<lpage>D918</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkm1009</pub-id>
<pub-id pub-id-type="pmid">18032438</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keiser</surname><given-names>M. J.</given-names></name><name><surname>Roth</surname><given-names>B. L.</given-names></name><name><surname>Armbruster</surname><given-names>B. N.</given-names></name><name><surname>Ernsberger</surname><given-names>P.</given-names></name><name><surname>Irwin</surname><given-names>J. J.</given-names></name><name><surname>Shoichet</surname><given-names>B. K.</given-names></name></person-group> (<year>2007</year>). <article-title>Relating protein pharmacology by ligand chemistry</article-title>. <source>Nat. Biotechnol.</source>
<volume>25</volume>, <fpage>197</fpage>–<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1038/nbt1284</pub-id>
<pub-id pub-id-type="pmid">17287757</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name><name><surname>Butte</surname><given-names>A. J.</given-names></name><name><surname>Swamidass</surname><given-names>S. J.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name></person-group> (<year>2016</year>). <article-title>A survey of current trends in computational drug repositioning</article-title>. <source>Brief. Bioinform.</source>
<volume>17</volume>, <fpage>2</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1093/bib/bbv020</pub-id>
<pub-id pub-id-type="pmid">25832646</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Lian</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Yan</surname><given-names>X.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Cheng</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Identification of novel key targets and candidate drugs in oral squamous cell carcinoma</article-title>. <source>Curr. Bioinform.</source>
<volume>14</volume>, <fpage>328</fpage>–<lpage>337</lpage>. <pub-id pub-id-type="doi">10.2174/1574893614666191127101836</pub-id>
</mixed-citation>
    </ref>
    <ref id="B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><name><surname>Wen</surname><given-names>X.</given-names></name><name><surname>Jorissen</surname><given-names>R. N.</given-names></name><name><surname>Gilson</surname><given-names>M. K.</given-names></name></person-group> (<year>2007</year>). <article-title>BindingDB: A web-accessible database of experimentally determined protein-ligand binding affinities</article-title>. <source>Nucleic Acids Res.</source>
<volume>35</volume>, <fpage>D198</fpage>–<lpage>D201</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkl999</pub-id>
<pub-id pub-id-type="pmid">17145705</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Kuang</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information</article-title>. <source>Nat. Commun.</source>
<volume>8</volume>, <fpage>573</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-017-00680-8</pub-id>
<pub-id pub-id-type="pmid">28924171</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olayan</surname><given-names>R. S.</given-names></name><name><surname>Ashoor</surname><given-names>H.</given-names></name><name><surname>Bajic</surname><given-names>V. B.</given-names></name></person-group> (<year>2018</year>). <article-title>Ddr: Efficient computational method to predict drug-target interactions using graph mining and machine learning approaches</article-title>. <source>Bioinformatics</source>
<volume>34</volume>, <fpage>1164</fpage>–<lpage>1173</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btx731</pub-id>
<pub-id pub-id-type="pmid">29186331</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawson</surname><given-names>A. J.</given-names></name><name><surname>Sharman</surname><given-names>J. L.</given-names></name><name><surname>Benson</surname><given-names>H. E.</given-names></name><name><surname>Faccenda</surname><given-names>E.</given-names></name><name><surname>Alexander</surname><given-names>S. P.</given-names></name><name><surname>Buneman</surname><given-names>O. P.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>The IUPHAR/BPS Guide to PHARMACOLOGY: An expert-driven knowledgebase of drug targets and their ligands</article-title>. <source>Nucleic Acids Res.</source>
<volume>42</volume>, <fpage>D1098</fpage>–<lpage>D1106</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkt1143</pub-id>
<pub-id pub-id-type="pmid">24234439</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>LightGBM: A highly efficient gradient boosting decision tree</article-title>. <source>Neural Inf. Process. Syst.</source>
<volume>2017</volume>, <fpage>3149</fpage>–<lpage>3157</lpage>. <pub-id pub-id-type="doi">10.5555/3294996.3295074</pub-id>
</mixed-citation>
    </ref>
    <ref id="B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaosheng</surname><given-names>C.</given-names></name><name><surname>Lu</surname><given-names>W.</given-names></name><name><surname>Xu</surname><given-names>Q.</given-names></name></person-group> (<year>2016</year>). <article-title>Deep neural networks for learning graph representations. national conference on artificial intelligence</article-title>. <source>Proc. AAAI Conf. Artif. Intell.</source>
<volume>30</volume> (<issue>1</issue>), <fpage>1145</fpage>–<lpage>1152</lpage>. <pub-id pub-id-type="doi">10.1609/aaai.v30i1.10179</pub-id>
</mixed-citation>
    </ref>
    <ref id="B25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>T. F.</given-names></name><name><surname>Waterman</surname><given-names>M. S.</given-names></name></person-group> (<year>1981</year>). <article-title>Identification of common molecular subsequences</article-title>. <source>J. Mol. Biol.</source>
<volume>147</volume>, <fpage>195</fpage>–<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1016/0022-2836(81)90087-5</pub-id>
<pub-id pub-id-type="pmid">7265238</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sousa</surname><given-names>S. F.</given-names></name><name><surname>Fernandes</surname><given-names>P. A.</given-names></name><name><surname>Ramos</surname><given-names>M. J.</given-names></name></person-group> (<year>2006</year>). <article-title>Protein-ligand docking: Current status and future challenges</article-title>. <source>Proteins</source>
<volume>65</volume>, <fpage>15</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1002/prot.21082</pub-id>
<pub-id pub-id-type="pmid">16862531</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>C.</given-names></name><name><surname>Zhong</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Drug-target interactions prediction using marginalized denoising model on heterogeneous networks</article-title>. <source>BMC Bioinforma.</source>
<volume>21</volume>, <fpage>330</fpage>. <pub-id pub-id-type="doi">10.1186/s12859-020-03662-8</pub-id>
</mixed-citation>
    </ref>
    <ref id="B28">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>S.</given-names></name><name><surname>Xz</surname><given-names>A.</given-names></name><name><surname>Mao</surname><given-names>D. B.</given-names></name><name><surname>Rp</surname><given-names>C.</given-names></name><name><surname>Sw</surname><given-names>A.</given-names></name><name><surname>Gan</surname><given-names>W. A.</given-names></name></person-group> (<year>2022</year>). <article-title>DeepFusion: A deep learning based multi-scale feature fusion method for predicting drug-target interactions</article-title>. <source>Methods</source>
<volume>204</volume>, <fpage>269</fpage>–<lpage>277</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymeth.2022.02.007</pub-id>
<pub-id pub-id-type="pmid">35219861</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>F.</given-names></name><name><surname>Hong</surname><given-names>L.</given-names></name><name><surname>Xiao</surname><given-names>A.</given-names></name><name><surname>Tao</surname><given-names>J.</given-names></name><name><surname>Zeng</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>NeoDTI: Neural integration of neighbor information from a heterogeneous network for discovering new drug-target interactions</article-title>. <source>Bioinformatics</source>
<volume>35</volume>, <fpage>104</fpage>–<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bty543</pub-id>
</mixed-citation>
    </ref>
    <ref id="B30">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Mezlini</surname><given-names>A. M.</given-names></name><name><surname>Demir</surname><given-names>F.</given-names></name><name><surname>Fiume</surname><given-names>M.</given-names></name><name><surname>Tu</surname><given-names>Z.</given-names></name><name><surname>Brudno</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Similarity network fusion for aggregating data types on a genomic scale</article-title>. <source>Nat. Methods</source>
<volume>11</volume>, <fpage>333</fpage>–<lpage>337</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.2810</pub-id>
<pub-id pub-id-type="pmid">24464287</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Pan</surname><given-names>Z.</given-names></name><name><surname>Rodriguez Paton</surname><given-names>A.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Song</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Multi-TransDTI: Transformer for drug-target interaction prediction based on simple universal dictionaries with multi-view strategy</article-title>. <source>Biomolecules</source>
<volume>12</volume>, <fpage>644</fpage>. <pub-id pub-id-type="doi">10.3390/biom12050644</pub-id>
<pub-id pub-id-type="pmid">35625572</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J. Z.</given-names></name><name><surname>Du</surname><given-names>Z.</given-names></name><name><surname>Payattakool</surname><given-names>R.</given-names></name><name><surname>Yu</surname><given-names>P. S.</given-names></name><name><surname>Chen</surname><given-names>C. F.</given-names></name></person-group> (<year>2007</year>). <article-title>A new method to measure the semantic similarity of GO terms</article-title>. <source>Bioinformatics</source>
<volume>23</volume>, <fpage>1274</fpage>–<lpage>1281</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btm087</pub-id>
<pub-id pub-id-type="pmid">17344234</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhu</surname><given-names>M.</given-names></name><name><surname>Bo</surname><given-names>D.</given-names></name><name><surname>Cui</surname><given-names>P.</given-names></name><name><surname>Shi</surname><given-names>C.</given-names></name><name><surname>Pei</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>) <article-title>Adaptive multi-channel graph convolutional networks</article-title>, <comment>arXiv</comment>. <fpage>1243</fpage>–<lpage>1253</lpage>. </mixed-citation>
    </ref>
    <ref id="B34">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y. B.</given-names></name><name><surname>You</surname><given-names>Z. H.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Yi</surname><given-names>H. C.</given-names></name><name><surname>Chen</surname><given-names>Z. H.</given-names></name><name><surname>Zheng</surname><given-names>K.</given-names></name></person-group> (<year>2020</year>). <article-title>A deep learning-based method for drug-target interaction prediction based on long short-term memory neural network</article-title>. <source>BMC Med. Inf. Decis. Mak.</source>
<volume>20</volume>, <fpage>49</fpage>. <pub-id pub-id-type="doi">10.1186/s12911-020-1052-0</pub-id>
</mixed-citation>
    </ref>
    <ref id="B35">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitebread</surname><given-names>S.</given-names></name><name><surname>Hamon</surname><given-names>J.</given-names></name><name><surname>Bojanic</surname><given-names>D.</given-names></name><name><surname>Urban</surname><given-names>L.</given-names></name></person-group> (<year>2005</year>). <article-title>Keynote review: <italic>In vitro</italic> safety pharmacology profiling: An essential tool for successful drug development</article-title>. <source>Drug Discov. Today</source>
<volume>10</volume>, <fpage>1421</fpage>–<lpage>1433</lpage>. <pub-id pub-id-type="doi">10.1016/S1359-6446(05)03632-9</pub-id>
<pub-id pub-id-type="pmid">16243262</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wishart</surname><given-names>D. S.</given-names></name><name><surname>Feunang</surname><given-names>Y. D.</given-names></name><name><surname>Guo</surname><given-names>A. C.</given-names></name><name><surname>Lo</surname><given-names>E. J.</given-names></name><name><surname>Marcu</surname><given-names>A.</given-names></name><name><surname>Grant</surname><given-names>J. R.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>DrugBank 5.0: A major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res.</source>
<volume>46</volume>, <fpage>D1074</fpage>–<lpage>D1082</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx1037</pub-id>
</mixed-citation>
    </ref>
    <ref id="B37">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>X. Y.</given-names></name><name><surname>Yin</surname><given-names>P. W.</given-names></name><name><surname>Wu</surname><given-names>X. M.</given-names></name><name><surname>Han</surname><given-names>J. X.</given-names></name></person-group> (<year>2021</year>). <article-title>Prediction of the drug-drug interaction types with the unified embedding features from drug similarity networks</article-title>. <source>Front. Pharmacol.</source>
<volume>12</volume>, <fpage>794205</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.794205</pub-id>
<pub-id pub-id-type="pmid">34987405</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>X. Y.</given-names></name><name><surname>Zhang</surname><given-names>S. W.</given-names></name><name><surname>He</surname><given-names>C. R.</given-names></name></person-group> (<year>2019</year>). <article-title>Prediction of drug-target interaction by integrating diverse heterogeneous information source with multiple kernel learning and clustering methods</article-title>. <source>Comput. Biol. Chem.</source>
<volume>78</volume>, <fpage>460</fpage>–<lpage>467</lpage>. <pub-id pub-id-type="doi">10.1016/j.compbiolchem.2018.11.028</pub-id>
<pub-id pub-id-type="pmid">30528728</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Qin</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>Y. H.</given-names></name><name><surname>Tao</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>C. Y.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Therapeutic target database update 2016: Enriched resource for bench to clinical drug target and targeted pathway information</article-title>. <source>Nucleic Acids Res.</source>
<volume>44</volume>, <fpage>D1069</fpage>–<lpage>D1074</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkv1230</pub-id>
<pub-id pub-id-type="pmid">26578601</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>X.</given-names></name><name><surname>Zhu</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Nussinov</surname><given-names>R.</given-names></name><name><surname>Cheng</surname><given-names>F.</given-names></name></person-group> (<year>2019</year>). <article-title>deepDR: a network-based deep learning approach to <italic>in silico</italic> drug repositioning</article-title>. <source>Bioinformatics</source>
<volume>35</volume>, <fpage>5191</fpage>–<lpage>5198</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btz418</pub-id>
<pub-id pub-id-type="pmid">31116390</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>X.</given-names></name><name><surname>Zhu</surname><given-names>S.</given-names></name><name><surname>Lu</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Target identification among known drugs by deep learning from heterogeneous networks</article-title>. <source>Chem. Sci.</source>
<volume>11</volume>, <fpage>1775</fpage>–<lpage>1797</lpage>. <pub-id pub-id-type="doi">10.1039/c9sc04336e</pub-id>
<pub-id pub-id-type="pmid">34123272</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>A similarity-based method for prediction of drug side effects with heterogeneous information</article-title>. <source>Math. Biosci.</source>
<volume>306</volume>, <fpage>136</fpage>–<lpage>144</lpage>. <pub-id pub-id-type="doi">10.1016/j.mbs.2018.09.010</pub-id>
<pub-id pub-id-type="pmid">30296417</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>S.</given-names></name><name><surname>Yasushi</surname><given-names>O.</given-names></name><name><surname>Gozoh</surname><given-names>T.</given-names></name><name><surname>Hiroshi</surname><given-names>M.</given-names></name></person-group> (<year>2005</year>). <article-title>A probabilistic model for mining implicit 'chemical compound–gene' relations from literature</article-title>. <source>Bioinformatics</source>
<volume>2</volume>, <fpage>ii245</fpage>–<lpage>ii251</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bti1141</pub-id>
</mixed-citation>
    </ref>
    <ref id="B44">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zong</surname><given-names>N.</given-names></name><name><surname>Wong</surname><given-names>R. S. N.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Wen</surname><given-names>A.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name></person-group> (<year>2021</year>). <article-title>Drug-target prediction utilizing heterogeneous bio-linked network embeddings</article-title>. <source>Brief. Bioinform.</source>
<volume>22</volume>, <fpage>568</fpage>–<lpage>580</lpage>. <pub-id pub-id-type="doi">10.1093/bib/bbz147</pub-id>
<pub-id pub-id-type="pmid">31885036</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
